Jeff Yass’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $603K | Buy |
44,359
+11,385
| +35% | +$191K | ﹤0.01% | 9460 |
|
|
2026
Q1 | $582K | Buy |
32,974
+18,598
| +129% | +$333K | ﹤0.01% | 9272 |
|
|
2025
Q4 | $273K | Buy |
14,376
+2,410
| +20% | +$50.7K | ﹤0.01% | 10173 |
|
|
2025
Q3 | $313K | Sell |
11,966
-3,762
| -24% | -$112K | ﹤0.01% | 10011 |
|
|
2025
Q2 | $557K | Buy |
15,728
+5,260
| +50% | +$201K | ﹤0.01% | 8921 |
|
|
2025
Q1 | $390K | Buy |
10,468
+2,911
| +39% | +$99.5K | ﹤0.01% | 9456 |
|
|
2024
Q4 | $275K | Sell |
7,557
-7,892
| -51% | -$255K | ﹤0.01% | 10023 |
|
|
2024
Q3 | $465K | Buy |
15,449
+6,769
| +78% | +$205K | ﹤0.01% | 8635 |
|
|
2024
Q2 | $289K | Buy |
+8,680
| New | +$316K | ﹤0.01% | 9530 |
|
|
2023
Q4 | – | Sell |
-5,786
| Closed | -$259K | – | 12352 |
|
|
2023
Q3 | $259K | Sell |
5,786
-2,711
| -32% | -$114K | ﹤0.01% | 9670 |
|
|
2023
Q2 | $354K | Sell |
8,497
-552
| -6% | -$21.9K | ﹤0.01% | 9103 |
|
|
2023
Q1 | $367K | Buy |
+9,049
| New | +$360K | ﹤0.01% | 9260 |
|
|
2022
Q4 | – | Sell |
-29,433
| Closed | -$1.49M | – | 12422 |
|
|
2022
Q3 | $1.49M | Buy |
29,433
+25,432
| +636% | +$1.2M | ﹤0.01% | 5614 |
|
|
2022
Q2 | $216K | Buy |
+4,001
| New | +$224K | ﹤0.01% | 10445 |
|
|
2021
Q4 | – | Sell |
-10,753
| Closed | -$388K | – | 13111 |
|
|
2021
Q3 | $388K | Sell |
10,753
-6,555
| -38% | -$229K | ﹤0.01% | 10004 |
|
|
2021
Q2 | $637K | Sell |
17,308
-6,251
| -27% | -$265K | ﹤0.01% | 8973 |
|
|
2021
Q1 | $1.06M | Buy |
+23,559
| New | +$990K | ﹤0.01% | 7579 |
|
|
2020
Q2 | – | Sell |
-4,223
| Closed | -$478K | – | 10128 |
|
|
2020
Q1 | $478K | Buy |
+4,223
| New | +$482K | ﹤0.01% | 7033 |
|
|
2019
Q4 | – | Sell |
-4,883
| Closed | -$782K | – | 9717 |
|
|
2019
Q3 | $782K | Buy |
4,883
+2,252
| +86% | +$331K | ﹤0.01% | 6249 |
|
|
2019
Q2 | $359K | Buy |
+2,631
| New | +$384K | ﹤0.01% | 7945 |
|
|
2018
Q4 | – | Sell |
-4,158
| Closed | -$670K | – | 8936 |
|
|
2018
Q3 | $520K | Buy |
+4,158
| New | +$560K | ﹤0.01% | 6440 |
|
|
2018
Q2 | – | Sell |
-6,127
| Closed | -$1.04M | – | 9603 |
|
|
2018
Q1 | $1.04M | Buy |
6,127
+564
| +10% | +$90.6K | ﹤0.01% | 5164 |
|
|
2017
Q4 | $982K | Buy |
+5,563
| New | +$988K | ﹤0.01% | 5272 |
|
|
2017
Q3 | – | Sell |
-1,340
| Closed | -$242K | – | 8809 |
|
|
2017
Q2 | $260K | Buy |
1,340
+197
| +17% | +$43K | ﹤0.01% | 7830 |
|
|
2017
Q1 | $255K | Sell |
1,143
-2,099
| -65% | -$495K | ﹤0.01% | 7633 |
|
|
2016
Q4 | $908K | Buy |
3,242
+422
| +15% | +$115K | ﹤0.01% | 5735 |
|
|
2016
Q3 | $713K | Buy |
2,820
+1,654
| +142% | +$439K | ﹤0.01% | 5429 |
|
|
2016
Q2 | $388K | Sell |
1,166
-2,791
| -71% | -$882K | ﹤0.01% | 6542 |
|
|
2016
Q1 | $1.38M | Sell |
3,957
-59
| -1% | -$20.5K | ﹤0.01% | 4462 |
|
|
2015
Q4 | $922K | Sell |
4,016
-7,754
| -66% | -$1.99M | ﹤0.01% | 5572 |
|
|
2015
Q3 | $3.63M | Buy |
11,770
+9,769
| +488% | +$2.3M | ﹤0.01% | 3170 |
|
|
2015
Q2 | $460K | Buy |
+2,001
| New | +$496K | ﹤0.01% | 7783 |
|
|
2015
Q1 | – | Sell |
-612
| Closed | -$187K | – | 9403 |
|
|
2014
Q4 | $225K | Buy |
+612
| New | +$255K | ﹤0.01% | 8619 |
|
|
2014
Q2 | – | Sell |
-660
| Closed | -$455K | – | 9740 |
|
|
2014
Q1 | $471K | Buy |
+660
| New | +$440K | ﹤0.01% | 6824 |
|
|
2013
Q4 | – | Sell |
-304
| Closed | -$310K | – | 8966 |
|
|
2013
Q3 | $310K | Buy |
304
+129
| +74% | +$153K | ﹤0.01% | 7157 |
|
|
2013
Q2 | $269K | Buy |
+175
| New | +$278K | ﹤0.01% | 6978 |
|
Other funds holding BIS
Jeff Yass's BIS Position: Q2 2026 in Review
Jeff Yass increased its ProShares UltraShort NASDAQ Biotechnology (BIS) stake by 35% in Q2 2026, buying an estimated $191K and bringing the position to 44,359 shares worth $603K. The position accounts for ﹤0.01% of the portfolio, ranked #9460.
Jeff Yass first reported a position in BIS in Q2 2013 and has held it in 36 quarters since. The position peaked at $3.63M in Q3 2015. 2 funds tracked by Wall St. Rank hold BIS as of Q2 2026.
- Jeff Yass held 44,359 shares of ProShares UltraShort NASDAQ Biotechnology worth $603K as of Q2 2026.
- Jeff Yass bought 11,385 ProShares UltraShort NASDAQ Biotechnology shares in Q2 2026, an estimated $191K.
- ProShares UltraShort NASDAQ Biotechnology made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #9460 holding.
- Jeff Yass first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q2 2013 and has held it in 36 quarters since.
- Jeff Yass's ProShares UltraShort NASDAQ Biotechnology position peaked at $3.63M in Q3 2015.
- 2 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.